Lion Point Capital, LP Cti Biopharma Corp Transaction History

Lion Point Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.2 - $6.01 $13 Million - $18.6 Million	-3,101,072 Reduced 83.75%	601,579 $2.53 Million
Q4 2022 Feb 14, 2023	SELL	$4.45 - $6.17 $3.06 Million - $4.24 Million	-686,895 Reduced 15.65%	3,702,651 $22.3 Million
Q3 2022 Nov 14, 2022	SELL	$5.36 - $7.43 $5.9 Million - $8.17 Million	-1,100,000 Reduced 20.04%	4,389,546 $11.7 Million
Q1 2022 May 16, 2022	BUY	$1.9 - $5.23 $8.11 Million - $22.3 Million	4,265,951 Added 348.64%	5,489,546 $25.6 Million
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.86 $1.76 Million - $3.5 Million	1,223,595 New	1,223,595 $3.03 Million

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Lion Point Capital, LP with notifications on news.